Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

OMER vs CAMP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OMER Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

OMER Overall Winner 6-Pillar Tally: OMER 3 – 2 CAMP (1 Tie) Matrix Metrics: OMER 8 – 2 CAMP

As of Nov 17, 2026, Omeros Corporation (OMER) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OMER carries a Unified Composite Score of 50.8/100 (HOLD) at $13.94 (73.0x Forward P/E, -189.5% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $4.00 (N/M Forward P/E, -991.8% operating margin).

  • Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (50.8/100 HOLD vs. CAMP 43.9/100 HOLD) and 2.00β · 82% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OMER is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OMER vs CAMP
OMER NASDAQ Head-to-Head Winner
Omeros Corporation
Pharmaceutical Preparations
$13.94
-16.43% 1D
Market Cap $1.3B
TTM Revenue $27M
Forward P/E 73.0x
Beta / 30D Vol 2.00β · 82% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.6%), weak momentum, RSI 30
RSI-14: 30.3 · SMA20: $17.29 · SMA50: $18.11
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$4.00
+3.63% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.35β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84

6-Pillar Scorecard Institutional Category Breakdown (OMER 3 – 2 CAMP)

Columns: Metric · OMER · CAMP
1. Valuation Multiples OMER
Forward P/E 73.0x N/M
Trailing P/E 14.3x N/M
PEG Ratio 0.81x N/M
EV / Revenue 50.1x 26.6x
2. Growth & Scale OMER
Revenue Growth (YoY) +14.9% +138.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $27M $5.3M
Market Cap $1.3B $238.5M
3. Profitability & Quality OMER
Gross Margin 38.3% N/A
Operating Margin -189.5% -991.8%
Net Profit Margin 324.9% 0.0%
Return on Equity (ROE) -576.3% -146.1%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$49M -$26M
Cash Flow Margin N/A N/A
Net Cash / Leverage $97M Net Debt $97M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAMP
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 85.5% (28th %ile) N/A (N/A)
Put/Call OI Skew 0.18x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OMER (8) vs CAMP (2)
Institutional Metric OMER CAMP Criterion Row Edge
Market Capitalization
Scale
$1.3B $238.5M Larger Scale OMER
Trailing P/E Ratio
Valuation
14.3x N/M Lower Multiple OMER
Forward P/E Ratio
Valuation
73.0x N/M Lower Multiple OMER
Revenue Growth (YoY)
Growth
+14.9% +138.9% Higher Growth CAMP
Operating Margin (TTM)
Profitability
-189.5% -991.8% Higher Margin OMER
Net Profit Margin
Profitability
324.9% 0.0% Higher Margin OMER
Return on Equity (ROE)
Capital Efficiency
-576.3% -146.1% Higher ROE CAMP
52-Week Range Position
Momentum
50% ($7–$21) 23% ($3–$8) Stronger Trend OMER
Beta / 30D Volatility
Risk Regime
2.00β · 82% Vol 1.35β · 94% Vol Lower Realized Risk OMER
Unified Institutional Score
Composite Signal
50.8 / 100 (HOLD) 43.9 / 100 (HOLD) Higher Composite OMER
Trailing 12M Revenue (USD)
Operating Scale
$27M $5.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
38.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.81x PEG · 50.1x EV/Rev N/M PEG · 26.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$49M ($97M Net Debt) -$26M ($97M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +42.13 pp
OMER: -14.74% · CAMP: +27.39%
3M Horizon CAMP +10.22 pp
OMER: -24.2% · CAMP: -13.98%
6M Horizon OMER +20.07 pp
OMER: +16.46% · CAMP: -3.61%
1Y Horizon OMER +79.57 pp
OMER: +77.13% · CAMP: -2.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OMER Revenue CAMP Revenue OMER Op. Margin CAMP Op. Margin Margin Leader
FY2016 $40M N/A -130.4% N/A OMER
FY2017 $60M N/A -67.7% N/A OMER
FY2018 $30M N/A -375.7% N/A OMER
FY2019 $110M N/A -130.6% N/A OMER
FY2020 $70M N/A -212.6% N/A OMER
FY2023 N/A $0M N/A -14822.6% CAMP
FY2024 N/A $0M N/A -8142.3% CAMP
FY2025 N/A $0M N/A -1502.4% CAMP

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OMER BREAKDOWN
40d in phase · OBV DISTRIBUTION
Current IV 85.5%
IV Percentile 28th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OMER Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $16.68 · IV 90.2%

OMER Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,668)

Compare $1,668 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 90.2% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $18 / $20 Bull Call Spread

Buy 3x $18C · Sell 3x $20C · 32d

Net Entry $285 Debit
T+5d @ +5% Move +$22 (+8%)
Max Risk / Buffer $285 Capped
5d Edge & Liquidity 0.4x R:R · Liq A
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $18 / $15 Bear Put Spread

Buy 1x $18P · Sell 1x $15P · 32d

Net Entry $198 Debit
T+5d @ -5% Drop +$19 (+10%)
Max Risk / Buffer $198 Capped
5d Edge & Liquidity 0.5x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OMER Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -189.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OMER vs CAMP Key Questions & Quantitative Answers

As of Nov 17, 2026, Omeros Corporation (OMER) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OMER carries a Unified Composite Score of 50.8/100 (HOLD) at $13.94 (73.0x Forward P/E, -189.5% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $4.00 (N/M Forward P/E, -991.8% operating margin). Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (50.8/100 HOLD vs. CAMP 43.9/100 HOLD) and 2.00β · 82% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OMER is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OMER leads the Growth & Scale pillar: OMER posts +14.9% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (38.3% gross margin, -189.5% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), OMER cumulative revenue shifted +75.0% while CAMP shifted N/A. In operating R&D and SG&A reinvestment, OMER deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.

OMER screens cheaper on headline valuation multiples. OMER trades at 73.0x Forward P/E, 14.3x Trailing P/E, 0.81x PEG, and 50.1x EV/Revenue (unreported FCF margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OMER (-576.3% ROE) versus CAMP (-146.1% ROE) capital efficiency.

In options market volatility and institutional positioning, OMER carries 85.5% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.00β · 82% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.